Chemed Corp. (NYSE:CHE) shares hit a new 52-week high and low during mid-day trading on Tuesday . The company traded as low as $289.84 and last traded at $288.52, with a volume of 50062 shares changing hands. The stock had previously closed at $286.36.
A number of research analysts have issued reports on the stock. ValuEngine raised shares of Chemed from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Oppenheimer increased their target price on shares of Chemed from $270.00 to $275.00 and gave the company an “outperform” rating in a report on Friday, February 16th. Finally, Royal Bank of Canada reaffirmed a “hold” rating and issued a $258.00 target price on shares of Chemed in a report on Friday, February 16th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $261.33.
The company has a current ratio of 0.91, a quick ratio of 0.88 and a debt-to-equity ratio of 0.17. The firm has a market cap of $4,573.96, a PE ratio of 53.43, a PEG ratio of 2.64 and a beta of 1.05.
Chemed (NYSE:CHE) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $2.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.27 by $0.05. Chemed had a net margin of 5.89% and a return on equity of 30.04%. The business had revenue of $428.35 million during the quarter, compared to analysts’ expectations of $423.83 million. During the same period last year, the company posted $2.10 EPS. The company’s revenue was up 6.2% on a year-over-year basis. analysts predict that Chemed Corp. will post 10.72 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 19th. Stockholders of record on Monday, February 26th were paid a dividend of $0.28 per share. The ex-dividend date of this dividend was Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a dividend yield of 0.39%. Chemed’s dividend payout ratio (DPR) is 20.90%.
Chemed declared that its Board of Directors has authorized a share buyback program on Tuesday, March 6th that allows the company to buyback $150.00 million in shares. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.
In other news, VP Naomi C. Dallob sold 1,050 shares of the firm’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $257.00, for a total transaction of $269,850.00. Following the completion of the transaction, the vice president now directly owns 6,649 shares of the company’s stock, valued at approximately $1,708,793. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kevin J. Mcnamara sold 6,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $258.00, for a total transaction of $1,548,000.00. Following the transaction, the insider now directly owns 140,049 shares of the company’s stock, valued at $36,132,642. The disclosure for this sale can be found here. Company insiders own 4.90% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of the company. Elkfork Partners LLC purchased a new position in shares of Chemed during the 4th quarter worth approximately $390,000. Xact Kapitalforvaltning AB acquired a new stake in Chemed during the fourth quarter worth approximately $406,000. MetLife Investment Advisors LLC acquired a new stake in Chemed during the fourth quarter worth approximately $1,738,000. Metropolitan Life Insurance Co. NY acquired a new stake in Chemed during the fourth quarter worth approximately $1,208,000. Finally, Vident Investment Advisory LLC boosted its position in Chemed by 6.4% during the fourth quarter. Vident Investment Advisory LLC now owns 13,482 shares of the company’s stock worth $3,276,000 after acquiring an additional 814 shares during the last quarter. 94.78% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Macon Daily and is the property of of Macon Daily. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://macondaily.com/2018/04/17/chemed-che-hits-new-1-year-high-and-low-at-289-84.html.
Chemed Company Profile
Chemed Corporation provides hospice and palliative care services in the United States. It operates through two segments, VITAS and Roto-Rooter. The VITAS segment offers direct medical services, as well as spiritual and emotional counseling services to terminally ill patients. This segment offers its services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.